Lupus Erythematosus, Systemic

Immunology
6
Pipeline Programs
9
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
1
2
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
2100%
+ 7 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Genentech
GenentechCA - Oceanside
1 program
1
RituximabPhase 2/3Monoclonal Antibody1 trial
Active Trials
NCT00137969Completed262Est. Aug 2008
Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04236921Phase 21 trial
Active Trials
NCT01405196Completed183Est. Mar 2014
UP
UCB PharmaBelgium - Brussels
1 program
1
epratuzumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00113971Terminated20Est. Jun 2007
E
EisaiChina - Liaoning
1 program
1
E6742Phase 1/21 trial
Active Trials
NCT05278663Completed26Est. Sep 2023
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 705564Phase 11 trial
Active Trials
NCT03771885Withdrawn0Est. Jan 2020
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
Hematopoietic Cell TransplantationPhase 11 trial
Active Trials
NCT00325741TerminatedEst. Oct 2015
Verona Pharma
Verona PharmaUK - London
1 program
DXAN/A1 trial
Active Trials
NCT05590390Active Not Recruiting300Est. Dec 2024
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)N/A1 trial
Active Trials
NCT05141201Active Not Recruiting1,620Est. Nov 2025
Alliance Pharmaceuticals
1 program
Valera Smart Phone Application and Care Manager DashboardN/A1 trial
Active Trials
NCT05693571Enrolling By Invitation40Est. Feb 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GenentechRituximab
PfizerPF-04236921
UCB Pharmaepratuzumab
EisaiE6742
Boehringer IngelheimBI 705564
City TherapeuticsHematopoietic Cell Transplantation
Alliance PharmaceuticalsValera Smart Phone Application and Care Manager Dashboard
Verona PharmaDXA
AstraZenecaSAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

Clinical Trials (9)

Total enrollment: 2,451 patients across 9 trials

NCT00137969GenentechRituximab

A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

Start: May 2005Est. completion: Aug 2008262 patients
Phase 2/3Completed
NCT01405196PfizerPF-04236921

Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus

Start: Dec 2011Est. completion: Mar 2014183 patients
Phase 2Completed
NCT00113971UCB Pharmaepratuzumab

Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Start: Apr 2005Est. completion: Jun 200720 patients
Phase 2Terminated
NCT05278663EisaiE6742

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants

Start: Apr 2022Est. completion: Sep 202326 patients
Phase 1/2Completed
NCT03771885Boehringer IngelheimBI 705564

BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)

Start: Mar 2019Est. completion: Jan 20200
Phase 1Withdrawn
NCT00325741City TherapeuticsHematopoietic Cell Transplantation

Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus

Start: Jun 2004Est. completion: Oct 2015
Phase 1Terminated
NCT05693571Alliance PharmaceuticalsValera Smart Phone Application and Care Manager Dashboard

Engagement in CHildhood-Onset Systemic Lupus

Start: Dec 2024Est. completion: Feb 202740 patients
N/AEnrolling By Invitation
NCT05590390Verona PharmaDXA

Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)

Start: Dec 2022Est. completion: Dec 2024300 patients
N/AActive Not Recruiting
NCT05141201AstraZenecaSAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)

Start: Dec 2021Est. completion: Nov 20251,620 patients
N/AActive Not Recruiting

Related Jobs in Immunology

Regulatory Affairs Manager(Immunology), Korea

AbbVie
Seoul, Seoul
6h ago

Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)

AbbVie
Remote
7h ago

Product Specialist - Immunology

Johnson & Johnson
Kibbutz Shefayim, Center District, Israel
20h ago

Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine

Johnson & Johnson
Detroit, Michigan, United States
20h ago

Senior Medical Science Liaison, Dermatology - Indianapolis

Johnson & Johnson
Indianapolis, Indiana, United States
20h ago
$137K - $236K/yr

Field Reimbursement Manager - Rheumatology - Seattle, WA (North)

Johnson & Johnson
Seattle, Washington, United States of America
20h ago
$100K - $175K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

Related Indications

Rheumatoid Arthritis(475)Psoriasis(206)Ulcerative Colitis(151)Atopic Dermatitis(144)Crohn's Disease(140)Systemic Lupus Erythematosus(85)Arthritis, Rheumatoid(61)Plaque Psoriasis(53)Crohn Disease(49)Ankylosing Spondylitis(33)